Spark Therapeutics Inc (ONCE) Expected to Announce Quarterly Sales of $4.75 Million

Wall Street brokerages expect that Spark Therapeutics Inc (NASDAQ:ONCE) will announce sales of $4.75 million for the current quarter, according to Zacks. Four analysts have provided estimates for Spark Therapeutics’ earnings. The highest sales estimate is $15 million and the lowest is $1.3 million. Spark Therapeutics reported sales of $1.29 million in the same quarter last year, which would suggest a positive year-over-year growth rate of 268.2%. The company is scheduled to issue its next quarterly earnings results before the market opens on Tuesday, May 9th.

According to Zacks, analysts expect that Spark Therapeutics will report full-year sales of $4.75 million for the current fiscal year, with estimates ranging from $5.2 million to $45.06 million. For the next year, analysts expect that the company will report sales of $140.14 million per share, with estimates ranging from $38.56 million to $251.3 million. Zacks’ sales averages are an average based on a survey of analysts that that provide coverage for Spark Therapeutics.

Spark Therapeutics (NASDAQ:ONCE) last announced its quarterly earnings data on Tuesday, May 9th. The biotechnology company reported ($1.70) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.30) by $0.40. Spark Therapeutics had a negative net margin of 441.05% and a negative return on equity of 28.28%. The business had revenue of $1.27 million during the quarter, compared to analyst estimates of $1.35 million. During the same quarter in the prior year, the company earned ($0.95) earnings per share. The company’s quarterly revenue was down 1.6% on a year-over-year basis.

ONCE has been the topic of a number of research reports. Stifel Nicolaus reissued a “buy” rating and set a $76.00 target price on shares of Spark Therapeutics in a report on Monday, April 10th. Vetr lowered shares of Spark Therapeutics from a “buy” rating to a “hold” rating and set a $62.50 target price on the stock. in a report on Tuesday, January 10th. BMO Capital Markets reissued an “outperform” rating and set a $69.00 target price on shares of Spark Therapeutics in a report on Friday, April 7th. Jefferies Group LLC reissued a “hold” rating and set a $57.00 target price on shares of Spark Therapeutics in a report on Tuesday, January 10th. Finally, JPMorgan Chase & Co. set a $82.00 target price on shares of Spark Therapeutics and gave the stock a “buy” rating in a report on Wednesday, February 22nd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the company. Spark Therapeutics currently has a consensus rating of “Buy” and a consensus price target of $68.31.

ILLEGAL ACTIVITY NOTICE: This piece of content was originally posted by Chaffey Breeze and is the property of of Chaffey Breeze. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of US and international trademark and copyright legislation. The correct version of this piece of content can be read at https://www.chaffeybreeze.com/2017/05/19/spark-therapeutics-inc-once-expected-to-announce-quarterly-sales-of-4-75-million-updated.html.

Shares of Spark Therapeutics (NASDAQ:ONCE) traded up 3.80% during trading on Thursday, reaching $60.17. 593,243 shares of the company traded hands. The firm’s market capitalization is $1.87 billion. Spark Therapeutics has a 12-month low of $31.28 and a 12-month high of $65.99. The company has a 50 day moving average price of $54.28 and a 200 day moving average price of $55.85.

In other news, CFO Stephen W. Webster sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, April 25th. The shares were sold at an average price of $55.18, for a total value of $551,800.00. Following the transaction, the chief financial officer now owns 4,398 shares in the company, valued at approximately $242,681.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Anand Mehra sold 35,347 shares of the business’s stock in a transaction that occurred on Thursday, February 16th. The stock was sold at an average price of $65.03, for a total transaction of $2,298,615.41. The disclosure for this sale can be found here. Insiders sold a total of 226,143 shares of company stock worth $14,356,283 in the last 90 days. Corporate insiders own 9.60% of the company’s stock.

Hedge funds and other institutional investors have recently modified their holdings of the company. Russell Investments Group Ltd. purchased a new position in shares of Spark Therapeutics during the fourth quarter worth about $883,000. Endurant Capital Management LP purchased a new position in shares of Spark Therapeutics during the third quarter worth about $348,000. Baker BROS. Advisors LP purchased a new position in shares of Spark Therapeutics during the third quarter worth about $79,180,000. Rock Springs Capital Management LP increased its position in shares of Spark Therapeutics by 2.5% in the third quarter. Rock Springs Capital Management LP now owns 625,000 shares of the biotechnology company’s stock worth $37,538,000 after buying an additional 15,000 shares during the period. Finally, Ameriprise Financial Inc. increased its position in shares of Spark Therapeutics by 32.8% in the third quarter. Ameriprise Financial Inc. now owns 129,627 shares of the biotechnology company’s stock worth $7,786,000 after buying an additional 32,023 shares during the period. Hedge funds and other institutional investors own 83.97% of the company’s stock.

Spark Therapeutics Company Profile

Spark Therapeutics, Inc is a gene therapy company. The Company focuses on treating orphan diseases. It has a pipeline of product candidates targeting multiple rare blinding conditions, hematologic disorders and neurodegenerative diseases. Its pipeline includes a product candidate targeting choroideremia (CHM), which is in a Phase I/II clinical trial and a product candidate for hemophilia A, which is in a Phase I/II clinical trial.

5 Day Chart for NASDAQ:ONCE

Get a free copy of the Zacks research report on Spark Therapeutics (ONCE)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Spark Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Spark Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply